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Review/Analyses
International travel and HIV infection
C.F. von Reyn,`2 J.M. Mann,' & J. Chin'
Although human immunodeficiency virus (HIV) infection is a worldwide problem, its prevalence and pattern
vary from country to country. Accordingly, the risk to international travellers of acquiring HIV infection also
varies widely in different parts of the world, and depends principally on their behaviour. The risk of sexual
acquisition of HIV infection can be virtually eliminated by avoiding penetrative sexual intercourse with
intravenous drug users and persons who have had multiple sexual partners (such as prostitutes) or reduced
by the use ofcondoms. The risk ofparenteral exposure to HlVcan be reduced byavoiding parenteral drug use
and behaviour that is likely to lead to injury (with its attendant risk of requiring blood transfusion) and by
seeking medical facilities with adequate capabilities to screen blood donors for HIV and to sterilize
instruments. HIV screening of international travellers is an ineffective, costly, and impractical public health
strategy for limiting the worldwide spread of HIV infection. Travellers infected with HIV require specialized
advice regarding health precautions, prophylactic medications, and immunization.
The pandemic of human immunodeficiency virus
(HIV) infection and acquired immunodeficiency syn-
drome (AIDS) has raised a variety of issues related to
international travel. Individual travellers ask about
the risk of acquiring HIV infection during travel;
national governments consider whether entering
travellers should be screened for HIV infection; and
tourist organizations and international transport
companies attempt to prevent fear of AIDS from
disrupting the travel industry.
This article summarizes the current global
epidemiology of AIDS and HIV infection, considers
the risk of acquiring HIV infection during inter-
national travel, addresses the issue of HIV screening
of international travellers, and offers advice for
preventing HIV infection during international travel.
Finally, recommendations are provided for medical
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counselling of the prospective traveller who is HIV-
infected.
Global epidemiology of AIDS and
HIV Infections
A total of 222 740 cases ofAIDS had been reported to
WHO from 153 countries by 1 March 1990 (Table 1).
Cases have been reported from every continent.
These data should not be interpreted to indicate that
countries that have reported no AIDS cases, or those
that have reported few cases, are either free of or have
Table 1: Number of AIDS cases reported to WHOb
1 March 1990
No. of countries or territories
No. of reporting:
cases to WHO 0 cases > 1 case
Africa 41518 52 4 48
Americas 147159 44 0 44
Asia 588 37 12 25
Europe 31 581 30 1 29
Oceania 1894 14 7 7
Total 222 740 177 24 153
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a low prevalence of HIV infection. Few sero-
prevalence studies have been carried out, and there is
also significant underrecognition, underdiagnosis,
and underreporting of AIDS in many areas of the
world, especially in developing countries with limited
laboratory and clinical facilities.
Available data on reported AIDS cases and HIV
seroprevalence information permit a reasonable des-
cription of the current global patterns of AIDS and
HIV infection (Fig. 1). Distinct patterns have been
observed, and are presumably related to the different
times of introduction or extensive spread of HIV and
to different social and behavioural characteristics
(1,2).
In Pattern I countries, where HIV appears to
have spread extensively in the late 1970s or early
1980s, most AIDS cases are due to sexual transmis-
sion among homosexual and bisexual men, with only
a small percentage of cases being due to heterosexual
contact. Parenteral transmission is due principally to
intravenous drug use. Data from volunteer blood
donors indicate that the overall population
seroprevalence in such countries is less than 1%,
although in some groups with high-risk behaviour
(homosexual or bisexual men with multiple sexual
partners, and intraveous drug users), seroprevalence
may be 50% or higher. This pattern is observed in
North America, western Europe, Australia, New
Zealand, South Africa and many urban areas of
Latin America.
The epidemiological pattern in many Pattern I
countries is still evolving. For example, in many
Latin American countries HIV transmission among
heterosexuals who have had multiple sexual partners
has increased since the mid-1980s, to the extent that
this mode of transmission has become the predomi-
nant one. As a result of this shift, Latin America has
been reclassified as Pattern I/II (2).
In Pattern II countries, where extensive spread
of HIV probably began in the 1970s, most sexual
transmission occurs among heterosexuals and the
male-to-female ratio is approximately 1:1. Parenteral
transmission occurs in areas where blood may not be
routinely screened for antibodies to HIV and from
use of unsterile needles, syringes, and other skin-
piercing instruments. The overall population
seroprevalence among adults, especially in urban
areas, is usually over 1% and may range as high as
5-25%. Pattern II has been observed in central,
eastern, western, and southern Africa and in some
areas of the Caribbean.
In Pattern III countries, where HIV appears to
have been introduced in the early to mid-1980s,
information about AIDS cases is either incomplete or
the number of reported cases is insufficient to identify
the predominant modes of transmission. The pre-
valence of HIV infection among persons who practise
high-risk behaviours (e.g., male or female prostitutes)
is generally as low as HIV seroprevalence rates
among blood donors in the USA and Europe (i.e., 1
per several thousand), but these levels are increasing,
especially in south-east Asia. Pattern III occurs in
North Africa, the Middle East, eastern Europe, Asia,
the Pacific, and rural parts of Latin America.
Risk of acquiring HIV infection during
international travel
Sexual transmission
The risk of acquiring HIV from sexual activity
depends on: the risk that a sexual partner is infected;
and the type and number of sexual contacts with the
infected partner. Although the probability that a
partner is infected may be higher in some countries
than others, it is clear from the preceding summary
of the epidemiological situation that there is a risk
of exposure to HIV infection from sexual contact
throughout the world.
In areas described as Pattern I, sexual contact
with homosexual or bisexual men, intravenous drug
users, or persons who have had many sexual partners
(e.g., prostitutes) poses the highest risk of exposure.
In Pattern II areas, sexual contact with heterosexuals
who have had multiple sexual partners (especially
prostitutes) presents a substantial risk of exposure
(3-6).
In areas where HIV infection has been docu-
mented, prostitutes (male or female) and other
persons who have had many sexual partners have
the highest rates of HIV infection. In the USA,
HIV infection rates among female prostitutes are
0-30% in Las Vegas and south Florida, where the
rate of intravenous drug use is 0-7%, and 19-57%
in Miami and Newark, NJ, where most have a history of
intravenous drug use (7,8). In Europe, infection rates
are 0-2% among female prostitutes in Paris and
London, 1% among registered prostitutes in the
Federal Republic of Germany, and 30-78% among
prostitutes in Italy, Switzerland, and the Netherlands
who are intravenous drug users (8-10).
In urban areas of central, eastern, and southern
Africa, rates of HIV-1 infection among female pros-
titutes range from 6-90% (11-13). Among female
prostitutes in West Africa, rates of HIV-2 infection
range from 4-39% (14, 15). Studies of female prosti-
tutes in Asia and the Pacific indicate HIV infection
rates of 0-6% (16-19).
Among sexually active homosexual or bisexual
men, rates of HIV seropositivity are 49-70% in
urban areas in the USA (20,21), with the following
rates in various cities in other Pattern I areas: Stock-
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holm, 30% (22), Sydney, 39% (23), Buenos Aires,
29% (24), and Mexico City, 31% (25). Although the
incidence of new HIV infections among homosexual
or bisexual men has decreased markedly in recent
years (26), the prevalence remains relatively high
because of past infections.
Parenteral transmission
Blood and blood products. Although transfusion of
unscreened blood remains associated with a substan-
tial risk of HIV transmission in some areas of the
world, the likelihood that a blood transfusion would
be required during international travel is low, and
measures to protect the blood supply are being
increasingly implemented in developing countries,
especially in large urban areas.
In the USA, approximately 1 million persons are
transfused annually, with each person receiving an
average of 2.9 units of blood (27). If these figures are
applied to a typical international trip, the number of
persons requiring transfusion would be 1.3 per 10 000
per 2-week period. Among 1746 Swedish Interna-
tional Development Agency (SIDA) personnel who
were working in rural Africa, the incidence of illness
that required immediate hospitalization was 10 per
10000 per 2-week period. Accidents or surgical
operations that created a potential need for trans-
fusions accounted for less than half of these cases, i.e.,
a maximum of 5 per 10 000 per 2-week period (J.
Stenbeck, personal communication, 1987).
Recognition of the need to screen donor blood
for HIV is now widespread and has been implemen-
ted not only in the industrialized world, but also in
many developing countries (WHO, unpublished data
1987). In Africa, for example, donor blood is now
screened in one or more hospitals or clinics in
the major cities of most countries. Also, in
Latin America, HIV screening programmes for blood
donors are widely available in large urban areas and
capital cities where HIV is prevalent. In Asia, the
seroprevalence of HIV is exceedingly low or absent
among the blood-donating public, but countries are
nevertheless beginning to implement HIV screening
programmes.
Nedles and other skin-piercing Instruments
The sharing of needles by intravenous drug users is
associated with a very high risk of HIV transmission
in Pattern I countries (where other intravenous drug
users are likely to be infected) (28). However, in other
areas of the world, intravenous drug users may also
incur substantial risk of HIV infection if they share
drug injecting equipment. Such a risk has been
realized in Bangkok, for example, where the preva-
lence of HIV infection among the estimated 60000
intravenous drug users increased from approximately
1% in late 1987 to over 40% in mid-1989 (29).
Reusable medical instruments that have been
contaminated with HIV-infected blood or body fluids
and have not been adequately sterilized have been
implicated in the transmission of HIV (30). For
example, in a recent instance in the USSR, at least 41
children were infected with HIV through the reuse of
syringes that were not sterilized between patients (31).
In non-medical settings, reusable skin-piercing
instruments also create a risk of HIV transmission if
they are not properly sterilized or disinfected after
each use (e.g., tattoo or acupuncture needles, re-
usable ear-piercing devices, razors, and other cutting
devices) (32). HIV is easily inactivated by standard
methods of sterilization or disinfection, such as auto-
claving or boiling for 20 minutes (33,34).
How HIV Is not transmitted
Studies from around the world have failed to cor-
roborate that HIV is transmitted through casual
contact (35,36). There is no risk of acquiring HIV
infection by travelling on the same public con-
veyance, sharing a bathroom or eating utensils, or
shaking hands with an HIV infected individual, from
coughing, sneezing, or sharing food or drink.
The following pieces of evidence indicate that HIV
is not transmitted via insects (37): the age-specific
rates of HIV infection and disease do not fit the
pattern for arthropod-borne diseases (i.e., which have
high attack rates in young children) (1); rates of HIV
infection in Africa are higher in urban than rural
areas (1); serological studies of humans have failed to
show a relationship between the presence of antibody
to HIV and antibody to arboviruses (38); and HIV
does not replicate in cell lines derived from arthro-
pods (39).
HIV screening of International
travellers
According to the WHO International Health Regula-
tions, the only health document that can be required
from international travellers is a valid vaccination
certificate against yellow fever (40). Nevertheless,
some countries have considered also requiring from
entering travellers proof of their HIV-negative status
or of screening them for HIV infection. At least 40
countries have abandoned such proposals after more
careful consideration of the issues and consultation
with WHO. However, at least 50 countries have
policies that discriminate against travellers and
migrants with AIDS or HIV infection (41).
Since HIV infection is now present in every
WHO Bulletin OMS. Vol 68 1990.25o
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WHO Region and most countries of the world, even
total exclusion of foreign travellers would be unlikely
to prevent its introduction and spread within a
country. This would be especially true for those
countries where large numbers of international
travellers are returning nationals. Since some indi-
viduals with early HIV infection cannot be identi-
fied with currently available serological tests (42,43),
no screening programme, even if applied to all enter-
ing travellers, could completely prevent introduction
of HIV. Also, the screening of low-risk groups, which
cover the majority of travellers, would be likely to
identify more false positive than true positive persons
(44).
In addition, the logistic problems that would be
posed by programmes to screen travellers for HIV
infection would be enormous (45)." These include
decisions about whether to screen at entry or several
months afterwards (to exclude false negatives during
the early stages of infection); what to do with the
traveller while awaiting the test results; and a series of
complex data management, laboratory control, legal,
and ethical issues.
Screening international travellers for HIV might
also have adverse public health consequences; to
protect its travelling citizens, a country might fail
to report AIDS cases; and travellers with "AIDS-
free" certificates might engender a false sense of
security (as of early 1990, no such "official" certificates
were being issued by any government). Furthermore,
the costs of screening programmes would be sub-
stantial. In 1985, close to 100 million travellers cros-
sed international borders legally (World Tourism
Association, unpublished data), while many millions
more crossed land borders informally. Even at a
conservative total cost of approximately US$ 10 per
test, the expense of screening all international
travellers would be enormous. In addition to being
ineffectual, HIV screening programmes for inter-
national travellers would therefore divert already
scarce health resources from more effective control
efforts.
A panel of experts convened by WHO in March
1987 concluded that HIV screening programmes for
international travellers would "at best and at great
cost, retard only briefly the dissemination of HIV
both globally and with respect to any particular
country".' In a statement made in 1989, the Inter-
national AIDS Society also has taken a similar
' World Halth Organizaton. Report of the Consultation on Inter-
national Travel and HIV Infection 1987. Unpublished document
WHO/SPA/GLO/87.1.
position, arguing for freedom to travel for all persons
with HIV infection.b
HIV prevention for the international
traveller
Much concern has been generated about the poten-
tial hazards of international travel to areas where
there may be a high prevalence of HIV infections (i.e.,
New York, San Francisco, Zurich, central Africa,
etc.). Advice about prevention of HIV infection
should be offered to the international traveller
regardless of their destination.c In addition, travellers
may wish to consult their national embassy, mission,
or consulate in the country of destination for advice
in selecting health care facilities that provide
adequate sterilization methods and screened blood.
Plasma expanders (rather than blood) should be
considered if urgent resuscitation is necessary.
Consultation for the HIV-infected
traveller
In 1988, the US Public Health Service estimated that
1-1.5 million Americans were infected with HIV (26).
By 1989 WHO estimated that at least 5 million
persons had been infected globally with the virus (29).
Thus, increasingly, international travel of HIV-infec-
ted persons can be expected, and individual medical
advice should be offered to such persons who are
considering international travel. As with any
traveller, the physician should first review the
proposed itinerary to determine whether immuniza-
tions or prophylactic medications are recommended,
and to assess whether other advice (food and water
precautions, insect bite prevention, etc.) is necessary
(46,47). The physician should also determine whether
the patient is immunosuppressed, since this will
influence additional recommendations. If the patient
is or may be immunosuppressed, special medical
advice should be offered. This should include con-
sideration of the possible increased risk of acquiring
various infectious diseases (e.g., those caused by sal-
monella (48,49) or cryptosporidia (50)), especially in
developing countries, and possible increased mor-
bidity or mortality should infection occur (54). In
countries where these risks are significant or if recom-
mended means of prevention might either be ineffec-
lnlematlonal AIDS Society. Press briefing, Geneva, 30 May
1989.
1 See: AIDS information for travellers. WHO leaflet, 1987.
Requests for single copies of this leaflet should be sent to:
Director, Global Programme on AIDS, World Health Organization,
CH-1211 Geneva 27, Switzerland.
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tive or associated with significant side-effects, i.e.,
immunization with a live vaccine or use of a prophy-
lactic medication, the traveller should be advised to
consider avoiding some or all of these countries on
the proposed itinerary.
Medical care
Persons with symptomatic disease, e.g., AIDS or
AIDS-related conditions, should consider the
medical care facilities in areas they may wish to visit,
insurance coverage, and the attitude of the host
country to treating patients with HIV infection
(current information may be solicited from the
traveller's embassy, mission, or consulate in the des-
tination country). Persons with overt HIV disease
may be prevented from entering countries or de-
ported if they are identified.
Prevention of food-, water-, and vectorborne
diseases
General recommendations for all international
travellers to areas where standards of environmental
or personal hygiene are low include the following:
avoid water unless it has been boiled, chemically
treated, or is bottled and carbonated; avoid ice unless
it has been prepared from boiled water; and avoid
vegetables and fruits that cannot be cooked or peeled
(46,47). Shellfish should be steamed for 4-6 minutes
or avoided if such preparation cannot be assured (52);
although this is a general recommendation for all
individuals, an increased susceptibility to septicaemia
from Vibrio spp. makes compliance with this
guideline especially important for those who are
immunosuppressed (53). Exposure to mosquitos can
be reduced by the use of insect repellents and protec-
tive clothing (46).
Prophylactic medications
Routine chemoprophylaxis for traveller's diarrhoea is
no longer recommended (46,47); however, antibiotics
are often provided to international travellers for 3-5
days' self-treatment of diarrhoea. The following drugs
are used to treat such diarrhoea: trimethoprim-
sulfamethoxazole, trimethoprim, doxycycline, and
ciprofloxacin (47, 54). Ciprofloxacin and trimetho-
prim-sulfamethoxazole are perhaps to be preferred
since they protect against salmonella. However, an
increased rate of hypersensitivity to sulfa drugs has
been described in patients with AIDS (55). Oral
rehydration salts, such as those recommended by
WHO, should be carried by travellers to treat diar-
rhoea associated with significant fluid loss (46).
Antispasmodics, e.g., loperamide, should also be
provided, but should be used judiciously to avoid
prolongation of symptoms, and should not be used if
inflammatory diarrhoea, i.e., blood or mucous in the
stool, is present (56).
Chloroquine may be taken for routine anti-
malarial prophylaxis, although the possible immuno-
suppressive effect from this drug should be recog-
nized (57). Standard reference works should be con-
sulted to determine whether prophylaxis or presump-
tive treatment for chloroquine-resistant Plasmodium
falciparum (CRPF) should also be provided (based on
the traveller's itinerary) (46,47). In consulting these
references, the physician should be aware of
additional considerations for persons with AIDS.
Pyrimethamine-sulfadoxine should probably be
avoided in situations where it is still recommended
for prophylaxis (e.g., prolonged travel to areas with
CRPF) because of the increased risk of side-effects in
persons with AIDS. However, pyrimethamine-sulfa-
doxine can be used for presumptive treatment if an
alternative is not available (58,59). Where available
(approval for use in the USA is pending), mefloquine
is an alternative drug for prevention and treatment of
CRPF and for P. falciparum that is resistant to
sulfadoxine-pyrimethamine (46,47). Doxycycline
may also be administered to AIDS patients in areas
where its use is recommended for malaria pro-
phylaxis (e.g., rural Thailand) (47). Where available,
daily doses of proguanil and weekly doses of
chloroquine may be used for prophylaxis ofCRPF in
East Africa (47).
Immunization
Decisions about immunizing HIV-infected persons,
including those who travel, must weigh up the risks
and benefits of immunization against the risk of
acquiring the vaccine-preventable disease. Sero-
logical responses to both live and inactivated vac-
cines are generally diminished in HIV-infected
individuals in proportion to their degree of immuno-
suppression, and adverse reactions to live vaccines
(BCG and smallpox) have been reported in HIV-
infected infants and adults (60,61). InactivMted
vaccines (e.g., those against diphtheria-tetanus or
typhoid fever) are not associated with an increased
rate of adverse effects in persons who are immuno-
suppressed, and may be administered to individuals
with HIV infection (60).
Live vaccines, including yellow fever vaccine, are
generally contraindicated for immunosuppressed
patients, such as those with symptomatic HIV infec-
tion (62). For individuals with asymptomatic HIV
infection, the risk of serious adverse reactions to live
vaccines has not been documented but must be
considered a possibility. For this reason, alternatives
should be provided. In the case of yellow fever
WHO Bulletin OMS. Vol 68 1990.2S
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vaccine, avoiding travel to areas where yellow fever is
endemic represents one option. For poliovaccine, the
inactivated rather than live attenuated vaccine
should be administered. Although measles vaccine is
a live attenuated vaccine, it has been given to persons
with symptomatic HIV infection without leading to
complications (60), and should be considered for
nonimmune HIV-infected travellers to areas where
measles is prevalent (e.g., developing countries) (63).
If vaccination against yellow fever is required by
the host country but is contraindicated for the
traveller, the physician should indicate on the Inter-
national Certificate of Vaccination that the indi-
vidual concerned has a medical exemption. However,
it should be made clear to the traveller that such
medical exemptions may not always be accepted by
the host country.
Preventing HIV transmission
HIV-infected persons should: refrain from donating
blood, semen, or tissue; notify potential sexual part-
ners of their HIV status and observe safe sex prac-
tices; inform health care providers of the need for
blood precautions; and avoid recreational use or
sharing of needles.
Conclusions
The global patterns and prevalence of HIV infections
vary widely from country to country, but the routes
of HIV transmission have been documented to be the
same throughout the world. The behaviours that put
persons at risk of being infected with HIV are
therefore similar worldwide. Preventive measures
against sexual transmission of HIV are also the same
worldwide, regardless of whether the individual is a
traveller or a resident of a given country. Health
care providers need to be able to discuss sensitive
issues, such as sexual behaviour, openly in clear and
easily understood language in order to protect their
patients, whether or not they are international travel-
lers.
The risk of travellers acquiring HIV infection
from infected needles or blood is greater in areas
where HIV is prevalent and routine screening of
blood for HIV antibodies has not been fully estab-
lished. However, this increased risk can be minimized
by seeking health care at facilities where such screen-
ing is carried out routinely.
International travel is as safe today as it ever has
been, and it can also be safe from HIV infection if
travellers are properly informed about how the virus
is and how it is not transmitted, and if travellers
adhere to simple precautions regarding sexual
behaviour and receipt of injections or blood.
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R6sum6
Voyages Internatlonaux et Infection par le VIH
La pandemie d'infection par le virus de l'immuno-
deficience humaine (VIH) et du syndrome
d'immunodeficience acquise (SIDA) a souleve un
certain nombre de problemes lies aux voyages
internationaux. Bien que l'infection par le VIH soit
un probleme mondial et que sa prevalence et ses
modalites varient de pays a pays, les voies de
transmission du VIH sont les memes dans le
monde entier. Le risque de contracter une infection
par le VIH peut cependant varier tres largement
dans differentes parties du monde. On trouvera ici
un resume sur l'epidemiologie mondiale actuelle
du SIDA et des infections par le VIH, sur le risque
de contracter une infection par le VIH pendant
un voyage international, des conseils pour prevenir
l'infection par le VIH pendant un tel voyage, et des
considerations sur le d6pistage du VIH chez les
voyageurs internationaux.
Les mesures preventives contre la transmis-
sion sexuelle du VIH sont les m6mes dans le monde
entier, qu'il s'agisse d'un voyageur ou d'un resident
d'un pays donne. Le risque d'etre infecte par voie
sexuelle peut etre 6limine en evitant les rapports
sexuels avec penetration, ou reduit en evitant
d'avoir des contacts sexuels avec des utilisateurs
de drogues par voie intraveineuse et des person-
nes qui ont eu des partenaires sexuels multiples
(comme les prostituees), et par l'emploi de preser-
vatifs. Le personnel soignant doit etre en mesure
de discuter de problemes delicats, comme le com-
portement sexuel, de fa,on ouverte et dans un
langage clair et facile a comprendre, de facon a
proteger les patients, qu'ils soient ou non des
voyageurs internationaux. Le risque d'exposition
au VIH par voie parenterale peut etre reduit en
evitant l'emploi de medicaments par cette voie et
des comportements susceptibles de provoquer des
blessures (avec le risque concomitant de la n6ces-
site d'une transfusion sanguine) et en s'adressant
pour des soins medicaux a des etablissements
ayant les capacites voulues pour depister les don-
neurs de sang pour le VIH et pour steriliser
les instruments. Le depistage du VIH chez des
voyageurs internationaux est une strategie de
sante publique inefficace, couteuse et non prati-
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cable pour limiter la diffusion mondiale de l'infec-
tion par le VIH.
Un voyage international est aussi depourvu de
danger aujourd'hui qu'il l'a jamais W, et tout
risque d'infection par le VIH peut etre evite si les
voyageurs sont informes de fa9on voulue sur la
fa9on dont le VIH est et n'est pas transmis et s'ils
observent de simples precautions dans leur com-
portement sexuel et s'ils evitent les injections ou
de recevoir du sang.
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